78 results about "Furosemide" patented technology

Host cells expressing HM74 were used to obtain furosemide-like molecules with agonist activity having the following structure formula:

The invention relates to a method for simultaneously detecting seven slimming chemical components which are illegally added to traditional Chinese medicine, health food or cosmetics. According to the method, an appropriate mobile phase and a reasonable elution gradient are adopted during liquid-phase separation, so that the slimming components needing to be detected are effectively separated within 12 min, the analysis time of a sample instrument is shortened by 88%, and the work efficiency is greatly increased. Additionally, the advantages of high separation ability of the HPLC (High Performance Liquid Chromatography) technology, high sensitivity and stronger qualitative ability of the mass spectrum and the like are combined, so screening and confirmation can be simultaneously completed during one operation. By using the method disclosed by the invention, the seven chemical components including sibutramine, fenfluramine, phenolphthalein, ephedrine, caffeine, N,N-bi-demethylation sibutramine and furosemide can be effectively separated, the inspection time can be shortened, and the slimming chemical components which are illegally added to the traditional Chinese medicine, the health food or the cosmetics can be accurately and effectively distinguished.

Improved, low-cost, scalable process for the preparation of 4-formylbenzofuran starting from 4-methylbenzofuran, wherein the novel 4-dibromobenzofuran is obtained as an intermediate . According to the method of the invention, 4-methylbenzofuran is brominated to obtain novel 4-dibromobenzofuran, which is then hydrolyzed to obtain 4-formylbenzofuran. 4-Formylbenzofura is a key intermediate in the production of isradipine for the treatment of hypertension and angina.

The invention relates to a one-step recovery and preparation method of cefuroxime sodium. The method comprises: dispersing cefuroxime sodium in a water-containing or non-aqueous mixed solvent of alcohol and ketone, adding hydrochloric acid or sulfuric acid at a temperature of 0-50°C, and reacting for 0.5-3 hours, and cefuroxime sodium is gradually converted into cefuroxime Fuuroctanoic acid is dissolved in the reaction system, and the by-product sodium chloride or sodium sulfate generated simultaneously is insoluble in the reaction system; Then, activated carbon is added for decolorization, filtered, and the by-product and activated carbon are filtered to obtain the cefuroxime acid solution; the obtained Cefuroxime sodium solution is mixed with sodium lactate or sodium isooctanoate aqueous or non-aqueous organic solvent solution to precipitate cefuroxime sodium crystals. The present invention adopts a one-step method for the recovery and preparation of cefuroxime sodium, without the need to separate and dry cefuroxime acid, thereby reducing the damage to cefuroxime acid, and the water content of the system is low during the recovery and preparation process, which is not suitable for unstable cefuroxime sodium Has a good protective effect.

The invention discloses a poria peel extract, prepared by the following steps: step (1) of drying and grinding poria peels, then dipping with ethanol and percolating, recovering ethanol, and concentrating to obtain brown pastes; step (2) of dissolving the obtained brown pastes with water, extracting with ethyl acetate, recovering ethyl acetate and concentrating to obtain pastes; step (3) of dissolving pastes obtained in the step (2) in ethanol, mixing with silica gel, loading in silica gel column with 100-200 meshes, eluting with petroleum ether-ethyl acetate eluent, collecting eluent, combining and concentrating to obtain the poria peel extract at the last. The extract provided by the invention has potassium-sparing and sodium excretion actions; diuretic action time of the extract is longer than that of furosemide; and the extract is featured with long-acting performance, low toxic side effects and so on, so that a new candidate diuretic medicine is provided for clinic.

The invention discloses a sodium sulfadiazine compound preparation for treating pig brain hydropsy, and a preparation method and application thereof, and belongs to the technical field of veterinary medicines. The sodium sulfadiazine compound preparation comprises sodium sulfadiazine, mannitol, furosemide, trimethoprim and the like. The sodium sulfadiazine compound preparation is scientific and reasonable in formula, safe in auxiliary material, controllable in quality, high in stability and low in cost, and a preparation process is simple and is suitable for industrial production.

The invention discloses an analysis method for determining the content of furfurylamine in furosemide, which comprises the following steps: dissolving furosemide with sodium hydroxide, neutralizing furosemide with hydrochloric acid, determining furosemide by high performance liquid chromatography, and taking a mixed solution of phosphate buffer salt and acetonitrile as a mobile phase by using a C18 chromatographic column. The invention provides a method for quickly determining furfurylamine in furosemide, which is strong in specificity, high in sensitivity, high in accuracy, simple and convenient to operate and capable of more effectively controlling the quality of furosemide.

The invention belongs to the technical field of pharmacy and discloses a preparation method of furosemide. The preparation method comprises putting 2, 4-dichloro-5-sulfamoylbenzoic acid and an acid-binding agent into an appropriate solvent, heating the solution to a certain temperature in an inert gas protective atmosphere, dropwisely adding furfuryl amine into the solution, after the reaction, adjusting pH through an acid so that crystals are precipitated, filtering the crystals to obtain a furosemide crude product, refining the crude product through an organic solvent-water mixed solvent, adjusting pH to greater than 7, carrying out heating so that the crude product is dissolved, carrying out decoloration through activated carbon, carrying out hot filtration, adjusting pH of the filtrate through an acid so that solids are precipitated and carrying out filtration and drying to obtain furosemide. The preparation method utilizes cheap and easily available raw materials, has a high conversion rate, less side products and high product purity, has simple processes and is suitable for industrial production. A HPLC analysis result shows that purity is greater than or equal to 99.0% and a total yield is 71.2%.

The invention discloses a compound sarafloxacin hydrochloride injection, its preparing process and use thereof, wherein the injection comprises (by weight portions) sarafloxacin hydrochloride 5-20 parts, maize flour 0.25-5 parts, ethanol 50-300 parts, methyl glycol 50-300 parts. The preparing process consists of steps of weighing each constituents, charging water for injection and stirring, adjusting acidity to 9.5-11 with hydrochloric acid or sodium-hydroxide, and charging water for injection to 1000ml.

The invention provides a preparation method of and application of a compound Haqing injection in preparing a preparation for atomizing and rectal administration . The preparation is a combination of the compound Haqing injection and one or more of ambroxol, potassium dehydroandrogrpholide succinate, furosemide and dexamethasone, is mainly used for atomizing and rectal administration and has remarkable effect on treating respiratory tract diseases such as respiratory tract infection, bronchial asthma and bronchitis.

The present invention is orally taken furosemide solution and its application in ultrasonic examination. Of the furosemide solution, each 100 ml contains furosemide in 10-30 mg. The orally taken furosemide solution is prepared through adding furosemide into distilled water, regulating pH value and other steps. The orally taken furosemide solution is applied in ultrasonic imaging examination, and can promote urination fast to fill bladder so as to obtain clear ultrasonic image.

The invention discloses a method for determining the concentration of furosemide in plasma by using liquid chromatography-mass spectrometry. The concentration of furosemide in the plasma is determinedby using a liquid chromatography-mass spectrometry system; taking a sample to be tested first, and adding a certain amount of mixed organic solvent for extraction twice; after pretreatment, performing chromatographic column separation, and then detecting by using a mass spectrometry detector. The method for determining the concentration of furosemide in the plasma by using the liquid chromatography-mass spectrometry disclosed by the invention has the advantages of rapid, accurate, high sensitivity and simple operation, and provides a basis for determining the blood concentration of furosemide; and the plasma standard curve linear range of the method is 10 to 2000 ng/mL, and the intra-assay and inter-assay precisions RSDs are less than +/-15%, which is suitable for determining the concentration of furosemide in the plasma.

The invention relates to a furosemide oral solution and a preparation method thereof. The furosemide oral solution contains a cellulose derivative and a sweet synergist with specific contents, and iscompounded with furosemide, propylene glycol, a diluent, a sweetening agent and essence; and on the premise of ensuring long-term stability of a preparation, the astringent taste of the conventional furosemide oral solution can be improved into a smooth, fragrant, sweet and rich taste on the whole.

The invention discloses a furosemide chewable tablet used for dogs and cats. The invention overcomes the poor palatability defect of the prior tablet to promote the thorough chewing absorption by dogs and cats, so as to effectively guarantee the medicine-supply dose, to enhance the cure rate of diseases of dogs and cats and to reduce the medicine waste. The tablet of the invention comprises the following components represented by weight-percentage: 1 to 5 percent of aspartame; 20 to 30 percent of a mixture of oral dextrose and degreased milk powder; the ratio of 1:1 to 1:4 between the oral dextrose and degreased milk powder in the mixture; 40 to 60 percent of excipient; 0.5 to 1 percent of glidant and 10 to 30 percent of furosemide.

The invention relates to the treatment of ascites, and especially refractory ascites, with an orally bioavailable prodrug of dopamine. A preferred prodrug of dopamine is docarpamine. In one embodiment treated patients are, prior to treatment, on doses of furosemide >80 mg/day and/or spironolactone >100 mg/day or equivalent doses of an alternative loop-acting and/or distal-acting diuretic. The ascites treated by the invention are typically caused by liver cirrhosis due to alcohol or non-alcoholic fatty liver disease and generally not due to viral hepatitis or primary biliary cholangitis. Preferred dosing is greater that 2250 mg per day, with more preferred doses exceeding 3500 mg per day.